Search clinical trials for: Rilpivirine (RPV) LA

Total 2387 results

Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
ViiV Healthcare
Janssen, LP

Completed

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

HIV Infections

United States, Canada
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

Pregnancy | HIV-1-infection | Postpartum

United States, South Africa
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Active, not recruiting

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)

HIV Infections

Thailand, United States, Botswana, Uganda, South Africa
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Recruiting

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

HIV Infections

United States, Puerto Rico
ViiV Healthcare
Janssen, LP

Completed

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)

HIV Infections

United States, Netherlands, Germany, Canada, Australia, Belgium, France, Spain, Ireland, Italy, United Kingdom, Austria, Japan, Switzerland
ViiV Healthcare
Janssen Pharmaceuticals

Completed

A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

HIV Infections

Germany, Netherlands, France, Belgium, Spain
ViiV Healthcare

Completed

Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)

HIV Infections

United States
Janssen Sciences Ireland UC
ViiV Healthcare

Approved for marketing

Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection

HIV
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada, Australia, Korea, Republic of, Italy, South Africa, Russian Federation, Argentina, Mexico, Sweden
ViiV Healthcare
GlaxoSmithKline; PPD

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (VOLITION)

HIV Infections

United States, France, Germany, Canada, Spain, Italy, Argentina, Chile, Puerto Rico
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

HIV Infections

United States, Germany, Netherlands, Spain, France, Canada, United Kingdom, Italy, South Africa, Russian Federation, Japan
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Human Immunodeficiency Virus Type 1 (HIV-1)

United States, Spain, Canada, United Kingdom, South Africa, Japan
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Active, not recruiting

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (HOLA)

HIV-1 Infection

Spain
Yale University
ViiV Healthcare

Not yet recruiting

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Hiv

United States
Boston Medical Center
ViiV Healthcare

Completed

Improving Treatment and Retention Adherence in Nontraditional Settings (I-TRAINS)

HIV Infections

United States
Instituto de Investigación Sanitaria de la Fundación...

Not yet recruiting

Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (IMAdART)

HIV Infections
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

HIV Infections

United States, Brazil
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

HIV Infections | Infection, Human Immunodeficiency Virus

Germany, Spain, France, United States, Canada
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

HIV Infections
Chiang Mai University

Unknown

Neurocognitive Function Improvement After Switching From Efavirenz to Rilpivirine

HIV-1-infection | Neurocognitive Dysfunction

Thailand
Janssen Research & Development, LLC

Active, not recruiting

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

Healthy

United States, Netherlands
Boehringer Ingelheim

Completed

Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers

Healthy
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
ASST Fatebenefratelli Sacco
Elisa Colella, M.D.; Valentina Di Cristo, M.D.; Massimo Galli, M.D.

Completed

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Human Immunodeficiency Virus

Italy
National Jewish Health
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Tailored Treatment to Enhance Risk Perception in Sleep Apnea

Obstructive Sleep Apnea (OSA)

United States
University College, London
London School of Hygiene and Tropical Medicine; MRC/UVRI and LSHTM Uganda Research... and other collaborators

Active, not recruiting

Long-Acting Treatment in Adolescents (LATA) (LATA)

HIV Infections | Hiv | HIV-1-infection | Paediatric Human Immunodeficiency Virus Infection

Uganda, Zimbabwe, Kenya, South Africa
Boehringer Ingelheim

Completed

Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers

Healthy
Gilead Sciences

Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

HIV-1 Infection

United States, Spain, United Kingdom, Canada, Puerto Rico, France, Belgium, Italy, Germany, Austria
Boehringer Ingelheim

Completed

Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers

Healthy
ViiV Healthcare

Completed

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

HIV Infections

Spain
Centers for Disease Control and Prevention, China
World Health Organization; Hubei Provincial Center for Disease Control and... and other collaborators

Completed

Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine (IPV)

Poliomyelitis

China
Lu Wang

Recruiting

CMRA for US-guided-MWA of Liver Tumors

Pain Control | Regional Anesthesia | Liver Tumors | Microwave Ablation

China
Philip Morris Products S.A.

Completed

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

Vaping | Nicotine Absorption

United States
Association of Urologic Oncology (AUO)
Eli Lilly and Company

Completed

Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA

Bladder Cancer

Germany
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Healthy

United States
Vaxtrials S.A.
Bill and Melinda Gates Foundation

Completed

Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life (IPV005)

Polio

Panama
Riyadh Colleges of Dentistry and Pharmacy

Completed

Vital Signs Changes During Dental Procedures

Vital Signs Changes During Dental Procedures

Saudi Arabia
Eastern Hepatobiliary Surgery Hospital

Completed

Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Hepatocellular Carcinoma | Portal Vein Tumor Thrombus | Laser Ablation

China
National Cancer Center, Korea

Unknown

Endoscopic Full Thickness Resection With Laparoscopic Assistance (EFTR-LA)

Gastric Subepithelial Tumor

Korea, Republic of
Kaohsiung Medical University

Completed

Hypochlorous Acid Mouthwash, Oral Bacteria, and Staphylococcus Aureus

Periodontal Diseases

Taiwan
Boston Children's Hospital

Suspended

Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis

Pulmonary Vein Stenosis

United States
Association of Urologic Oncology (AUO)

Unknown

Prospective Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy (SEAL)

Prostate Cancer

Germany
Rhode Island Hospital

Recruiting

Combined Injectable Treatment for HIV and OUD (CHOICE)

Opioid Use Disorder | Human Immunodeficiency Virus

United States
Kaneka Medical America LLC

Recruiting

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System (FSGSALLAGE)

Focal Segmental Glomerulosclerosis

United States
Parc Sanitari Sant Joan de Déu

Completed

Homeless Population and Mental Health: Impact of Primer la Llar Program

Mental Health Disorder
Bristol-Myers Squibb

Completed

Effect of the Atazanavir (ATV) 150L Mutation on Subsequent Treatment Response in HIV Infected Subjects

HIV Infection

United States, Argentina, Brazil, Guatemala, Mexico, Peru, South Africa
Fundacion SEIMC-GESIDA

Active, not recruiting

Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (MAFALDA-R)

HIV Infections | Fatty Liver Disease

Spain
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects

Infection, Human Immunodeficiency Virus

United States

3

Subscribe